DALLAS, March 17, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/ANPI
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Angiotech Pharmaceuticals Inc. (ANPI), a specialty pharmaceutical and medical device company, engages in the discovery, development and marketing of innovative technologies primarily focused on acute and surgical applications. The Company generates its revenue through sales of medical products and components, as well as from royalties derived from sales by its partners of products utilizing certain of its proprietary technologies. Its initial lead product, the TAXUS® drug-eluting coronary stent, which was co-developed and is now sold by Boston Scientific Corp., is implanted in over four million patients worldwide.
ANPI's research and development efforts focus on understanding and characterizing biological conditions that often occur concurrent with medical device implantation, surgery or acute trauma, including scar formation and inflammation, cell proliferation, bleeding and coagulation, infection and tumor tissue overgrowth. Its strategy is to utilize its various technologies in the areas of drugs, drug delivery, surface modification, biomaterials and medical devices to create and commercialize novel, proprietary medical products that reduce surgical procedure side effects, improve surgical outcomes, shorten hospital stays, or are easier or safer for a physician to use. ANPI operates in two segments: Pharmaceutical Technologies and Medical Products.
In the report, the analyst notes:
"Boston Scientific Corp. recently announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS(R) Express(2)(TM) Paclitaxel-Eluting Stent System or the Express(R) bare-metal stent. The results reportedly demonstrated that the stent significantly reduced ischemia-driven target lesion revascularization (TLR) at one year and binary in-stent restenosis at 13 months in diabetic patients. ..."
To read the entire report visit: http://www.stockpreacher.com/n/ANPI
See what investors are saying about ANPI at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.